Medline (NASDAQ:MDLN) Posts Earnings Results, Beats Expectations By $0.04 EPS

Medline (NASDAQ:MDLN) released its earnings results on Wednesday. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04, FiscalAI reports. The firm had revenue of $7.35 billion for the quarter. The firm’s quarterly revenue was up 10.7% on a year-over-year basis.

Here are the key takeaways from Medline’s conference call:

• Medline reported a strong start to 2026 with 11% top-line growth in Q1 and raised full?year organic sales guidance to 8.5%–9.5%, driven by Supply Chain Solutions and new customer implementations.
• Adjusted EBITDA declined 11% to $776 million and margins fell ~250 bps, with management citing higher cost of goods (including tariff impact) and continued operational investments as the main drivers.
• Company flagged ongoing macro headwinds — tariff volatility and the Middle East conflict — that could raise input and fuel costs later in 2026 and may prompt measured price actions if needed.
• Strategic initiatives progressed: Medline secured its first Canadian prime?vendor partnership with Mohawk Medbuy, began pilots of robotics with Symbotic, introduced automation (Pick Pack Pro) and is expanding its AI control tower Mpower, all intended to improve efficiency and drive future growth.
• Balance sheet and cash flow support investments — Q1 free cash flow of $316 million, $2.2 billion cash on hand and net leverage ~3.1x — and management said it will pursue strategic M&A or further deleveraging as opportunities arise.

Medline Stock Down 5.8%

Shares of Medline stock traded down $2.42 during trading on Friday, reaching $39.44. 6,742,450 shares of the company were exchanged, compared to its average volume of 5,541,202. Medline has a twelve month low of $34.89 and a twelve month high of $50.88. The business’s 50-day simple moving average is $44.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MDLN shares. Sanford C. Bernstein dropped their target price on Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a research report on Thursday. Tigress Financial boosted their target price on Medline from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. BMO Capital Markets boosted their target price on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Barclays started coverage on Medline in a research report on Monday, January 12th. They set an “overweight” rating and a $50.00 target price for the company. Finally, BTIG Research restated a “buy” rating and set a $55.00 target price on shares of Medline in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $50.69.

Institutional Investors Weigh In On Medline

A number of institutional investors have recently made changes to their positions in MDLN. Carlyle Group Inc. acquired a new stake in shares of Medline during the fourth quarter worth $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in shares of Medline during the fourth quarter worth $4,179,591,000. Vanguard Group Inc. acquired a new stake in shares of Medline during the fourth quarter worth $793,278,000. Morgan Stanley acquired a new stake in shares of Medline during the fourth quarter worth $636,807,000. Finally, Capital Research Global Investors acquired a new position in Medline in the fourth quarter valued at about $620,937,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline beat Q1 estimates with $7.35B in revenue (up ~10.7% YoY) and $0.33 EPS, and the company raised its full-year organic sales growth outlook — a growth beat that supports the long-term case. Medline Reports First Quarter 2026 Results
• Positive Sentiment: Several analysts reaffirm buy/outperform views and high targets (BTIG $55, Bernstein still “outperform”) signalling institutional conviction in Medline’s growth trajectory despite near-term noise. Analyst Ratings Coverage (Benzinga)
• Neutral Sentiment: Management discussed strategy and details on the earnings call; the transcript and investor presentation provide color on investments, margin drivers and supply-chain wins (useful for modeling future quarters). Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Medline launched an AI-powered “Mpower” platform aimed at supply-chain resiliency — a strategic product that could support service differentiation but with uncertain near-term financial impact. Medline Launches AI-Powered Mpower Platform
• Negative Sentiment: Profitability is under pressure: adjusted EBITDA fell ~11% and net income declined ~26% (tariffs, higher costs and IPO-related expenses cited). Those margin hits are a primary reason investors are selling into the rally. Q1 Earnings Discussion & Margin Details
• Negative Sentiment: Substantial insider/PE selling has been reported (large blocks sold by private-equity holders), which adds supply and downward pressure on the stock despite some insider purchases. Insider & Institutional Trading Summary
• Neutral Sentiment: Analyst tweaks: Sanford Bernstein trimmed its price target slightly (from $56 to $54) and Bank of America lowered a target to $53 while maintaining buys — these cuts reflect margin concerns but leave consensus on the stock broadly positive. Analyst Target Changes & Commentary

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.